Pfizer Limited

PFIZER.BO

Drug Manufacturers - General · Healthcare

Price

₹4975.10

+53.70 (+1.09%)

Market Cap

₹227.67B

Exchange

Bombay Stock Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Exceptional

Growth

Good

Cash Flow

Strong

Stability

Good

Valuation

Good

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

Pfizer Limited is the Indian subsidiary of Pfizer Inc., one of the largest pharmaceutical companies in the world. It makes and sells prescription medicines, vaccines, and consumer health products to hospitals, doctors, and pharmacies across India. Its portfolio includes well-known medicines for pain, infections, inflammation, and other common conditions.

The company earns money by selling its products to healthcare providers and distributors throughout India, operating primarily as a domestic business within the broader Indian pharmaceutical market. Pfizer Limited benefits from its parent company's global research and brand recognition, which gives it an edge over smaller local competitors. The key growth driver is India's expanding middle class and rising healthcare spending, though the company faces real risks from government price controls on essential medicines, which can limit how much it can charge for its products.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-39.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

₹0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

67.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

₹30.9B cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Pfizer Limited is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 45.8M (2022) → 45.7M (2026)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

63.2%

Premium pricing power — 63.2% gross margin

Profit after running costs

Operating Margin

35.7%

Excellent — 35.7% operating margin

Return on the money invested

ROCE

21.0%

Exceptional — 21.0% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+10.7%

Steady sales growth (+10.7% YoY)

Profit growth

EPS YoY

-9.1%

Earnings shrinking (-9.1% YoY)

Slight earnings drop. Typical near a cyclical low.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

82%

Modest — 82% of profit becomes cash

Spare cash per sale

FCF Margin

22.9%

Converts sales into free cash efficiently (22.9%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

114.96x

Comfortably covers interest (115.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

31.0x

Pricey — P/E 31.0

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year

P/E vs Forward

+4.3

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (31.0 → 26.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.54%

Small dividend — 1.54% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+186.4%

Dividend growing fast (186.4% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial